Adaptive randomization involves adjusting the probability of assignment to different treatment arms based on accumulating data throughout the trial. This is in contrast to traditional randomization, where participants have an equal chance of being assigned to any treatment group. In cancer trials, this can mean assigning more patients to treatments that appear more effective during the trial. The goal is to optimize patient outcomes while still maintaining scientific rigor.
